Canada Insurer Manulife & Guardant Health Form Exclusive Partnership to Provide Blood-Based Multi-Cancer Screening Test (Shield Multi-Cancer Detection) for 10 Most Common Cancers to Eligible Customers in Asia (Hong Kong, Singapore & Philippines) Starting 2026 April
17th March 2026 | Hong Kong
Canada insurer Manulife & Guardant Health have formed an exclusive partnership to provide blood-based multi-cancer screening test (Shield Multi-Cancer Detection) for 10 most common cancers to eligible customers in Asia (Hong Kong, Singapore & Philippines), starting in 2026 April. Announcement (16/3/26): “Manulife today announced an exclusive partnership with Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, becoming the first insurer in Asia to offer Guardant Health’s Shield Multi-Cancer Detection (MCD) test to customers in Hong Kong, the Philippines, and Singapore. Under the partnership, Manulife’s customers will have exclusive access to the Shield MCD test in these three launch markets in 2026, marking the first introduction of this innovative test in Asia to Manulife customers. This collaboration underscores both companies’ shared commitment to expanding access to innovative and proven health solutions that address real, unmet health needs … … The Shield MCD test will be available to eligible Manulife customers beginning April 2026. Cancer remains one of the leading causes of death in Asia[. With just a blood draw, the Shield MCD test screens for 10 of the most common cancers, many of which have high mortality rates in Asia. The test received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) in June 2025. This collaboration builds on the two companies’ existing relationship in Singapore to offer eligible customers access to the Guardant360 liquid biopsy test for advanced solid tumors and represents a shared vision of bringing new and advanced health solutions and expanding access to preventive care to more markets across Asia … … These efforts align with the Manulife Longevity Institute, a global research, thought leadership, innovation, advocacy, and community investment platform that aims to advance action on helping people live longer, healthier, more financially secure lives.”
“ Canada Insurer Manulife & Guardant Health Form Exclusive Partnership to Provide Blood-Based Multi-Cancer Screening Test (Shield Multi-Cancer Detection) for 10 Most Common Cancers to Eligible Customers in Asia (Hong Kong, Singapore & Philippines) Starting 2026 April “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
Steve Finch, President and CEO of Manulife Asia: “By being the first insurer in Asia to offer the Shield MCD test, we’re empowering our customers with a credible and valued service that encourages proactive health management. This exclusive partnership demonstrates our commitment to offering innovative and differentiated solutions to improve the health outcomes of our customers.”
Simranjit Singh, CEO of Guardant Health AMEA: “We are excited to partner with Manulife to introduce the Shield MCD test to Asia for the first time. Shield MCD has the potential to significantly lift screening rates across the region for the most prevalent cancers. This could significantly alleviate the burden of cancer across Asia by expanding access to cancer detection with just a blood draw. We look forward to the impact that this collaboration with Manulife will make in bringing this latest innovation in cancer screening to the Asian market.”
Harshal Shah, Chief Marketing Officer of Manulife Asia: “As part of this new partnership, Manulife is committed to providing underserved communities with access to the Shield MCD test. “This commitment underscores our dedication to prioritizing health and wellbeing so people can unlock life’s potential and live fuller, more prosperous lives at any age. Empowering health, wealth, and longevity is central to Manulife’s ambition. Through our partnership with Guardant Health, we look forward to advancing this mission for our customers and the communities we serve.”
Canada Insurer Manulife & Guardant Health Form Exclusive Partnership to Provide Blood-Based Multi-Cancer Screening Test (Shield Multi-Cancer Detection) for 10 Most Common Cancers to Eligible Customers in Asia (Hong Kong, Singapore & Philippines) Starting 2026 April
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
